Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price boosted by Royal Bank of Canada from $408.00 to $420.00 in a research report sent to investors on Tuesday morning,Benzinga ...

Bank of America upped its price target for Vertex Pharmaceuticals from $555 to $567, signaling growing confidence in the ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...

Pakistan's solar energy sector has gained momentum in recent years, with increasing investments in renewable energy infrastructure. The country has seen a steady rise in solar adoption across ...

Vertex Minerals (ASX:VTX) has begun trading shares on the OTCQB Venture Market in the US, under the ticker code VTXXF.

Vertex Minerals Ltd. is pleased to announce that its Ordinary Shares have been approved to trade on the OTCQB Venture Market in the United States of America and have commenced trading under the ticker ...

Pakistan's solar energy sector has gained momentum in recent years, with increasing investments in renew­able energy infrastructure. The country has seen a steady rise in solar adoption across ...

Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...

Shares of Vertex, Inc. (NASDAQ:VERX – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from ...

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $492.69, signifying a -1.96% move from its prior day's close.